as a positive control in high-performance liquid chromatography (HPLC)[1]
as a reference compound in high-performance liqiud chromatography (HPLC)[2]
as a pan-protein tyrosine phosphatase non-receptor type (PTPN) inhibitor to study its effects on the activated lymphocytes [3]
Biochem/physiol Actions
RK-682 is a specific and noncompetitive inhibitor of protein tyrosine phosphatase; It inhibited dephosphorylation activity of CD45 and VHR with IC50 54 and 2.0 microM and 4.5 microM against PTP1B.
Specific and noncompetitive inhibitor of protein tyrosine phosphatase.
Journal of Asian natural products research, 22(7), 603-617 (2019-07-20)
This present study was to evaluate the protein tyrosine phosphatase 1B (PTP1B) inhibitory activity of nine diterpenes isolated from seeds of Phalaris canariensis, as well as their effect on streptozotocin-nicotinamide-induced type 2 diabetic mice. Their structures were established by spectroscopic
Cancer immunology, immunotherapy : CII, 68(10), 1649-1660 (2019-09-29)
It has been shown that protein tyrosine phosphatase non-receptor type (PTPN) 3 inhibits T-cell activation. However, there is no definitive conclusion about how the inhibition of PTPN3 in lymphocytes affects immune functions in human lymphocytes. In the present study, we
International journal of molecular sciences, 21(11) (2020-05-31)
Heparan sulfate proteoglycan syndecan-1, CD138, is known to be associated with cell proliferation, adhesion, and migration in malignancies. We previously reported that syndecan-1 (CD138) may contribute to urothelial carcinoma cell survival and progression. We investigated the role of heparanase, an
Type 2 diabetes (T2D) constituted 90% of the global 387 million diabetes cases in 2014. The enzyme protein-tyrosine phosphatase 1B (PTP1B) has been recognized as a therapeutic target for treatment of T2D and its adverse complications. With the aim of
The clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) system, an RNA-guided nuclease for specific genome editing in vivo, has been adopted in a wide variety of organisms. In contrast, the in vitro application of the CRISPR/Cas9 system
Protein tyrosine phosphatases' catalytic mechanism involves transient phosphorylation.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.